Karyopharm Therapeutics | KPTI - Debt


Karyopharm Therapeutics reported $299.23M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Abbott USD 34.05B 20.19B Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.12B 222M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Pfizer USD 63.19B 536M Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Takeda JPY 4.94T 58.13B Jun/2026
Tectonic Therapeutic USD 876K 115K Dec/2024
TG Therapeutics USD 754.44M 884K Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Xencor USD 175.16M 12.58M Mar/2026